•
ZB
ZBIO
Zenas BioPharma, Inc. Common Stock
yahooPHARMACEUTICAL PREPARATIONS
--
Price Chart
Market Cap
1.05B
Volume
823.93K
52W High
$44.60
52W Low
$5.83
Open
$0.00
Prev Close
$20.88
Day Range
0.00 - 0.00
About Zenas BioPharma, Inc. Common Stock
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.
Latest News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO
GlobeNewswire Inc.•Jan 13
Chairman and CEO of Zenas BioPharma (ZBIO) Buys 36,928 Shares for $769,948
The Motley Fool•Oct 16
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO
GlobeNewswire Inc.•Jun 15
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma
GlobeNewswire Inc.•Jun 12
ZBIO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
GlobeNewswire Inc.•Jun 11
Zenas BioPharma, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; June 16, 2025 Deadline to file Lead Plaintiff Motion
GlobeNewswire Inc.•Jun 10
GoHealth, Inc. Investor News: If You Have Suffered Losses in GoHealth, Inc. (NASDAQ: GOCO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
GlobeNewswire Inc.•Jun 10
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ibotta, NET Power, Zenas BioPharma, and Avis Budget and Encourages Investors to Contact the Firm
GlobeNewswire Inc.•Jun 10